A new anemia drug developed by Takeda Pharmaceuticals has been accepted for review by the European Medicines Agency. The new drug is designed to be taken once a month for patients with anemia from chronic kidney disease and was discovered by Affymax.
If approved by the EMA, Takeda will market the product solely in Europe. If approved in the U.S., Takeda will market it with Affymax. The Food and Drug Administration is expected to make a decision by the March 27. The review process will test the drug when given in a dose once every four weeks and another drug that is taken three times per week.
Although anemia is a debilitating condition for chronic kidney disease patients on dialysis, appropriate management of this condition is onerous for patients and healthcare professionals,” said Dr Stuart Dollow, managing director, Takeda Global Research & Development Centre (Europe).
“Our programme illustrates the potential of peginesatide as an important once-monthly therapeutic option.”
Takeda also markets the type 2 diabetes drug, Actos, that has recently been in the media because of its increased risk of bladder cancer when taken for over a year. If this has happened to you or a loved one, contact the Actos lawsuit lawyers of Williams Kherkher today by calling 800-641-9810 today.